M. Han

TEK is a novel prognostic marker for clear cell renal cell carcinoma.

S. M. Park, Y. Kim, D. Lee, 2019, European review for medical and pharmacological sciences.

Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma

Xue Wu, Y. Shao, H. Bao, 2021, Neoplasia.

Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.

Qiang Wan, Y. Jing, M. Han, 2015, European review for medical and pharmacological sciences.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

C. Hofmeister, M. Cotreau, A. Tolcher, 2014, British Journal of Cancer.

Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

M. Cotreau, T. Mok, E. Tan, 2011, Journal of Clinical Oncology.

Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

M. Cotreau, M. Ahn, E. Tan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections in Critically Ill Patients: Focus on Novel Infusion Mode

Xiangqing Song, M. Han, 2022, Frontiers in Cellular and Infection Microbiology.

A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA)

Keunchil Park, T. Mok, E. Tan, 2012 .